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Abstract
Purpose Sporadic inclusion body myositis (sIBM) is an
autoimmune degenerative disease of the muscle, with
inflammatory infiltrates and inclusion vacuoles. Its patho-
genesis is not fully understood and the diagnosis is ham-
pered by its imprecise characteristics, at times
indistinguishable from other idiopathic inflammatory
myopathies such as polymyositis and dermatomyositis. The
diagnosis may be assisted by the detection of autoanti-
bodies targeting Mup44, a skeletal muscle antigen identi-
fied as cytosolic 50-nucleotidase 1A (cN-1A, NT5C1A). A
novel standardized anti-cN-1A IgG ELISA was developed
and its diagnostic performance was evaluated by two ref-
erence laboratories.
Methods Recombinant human full-length cN-1A was
expressed and purified, and subsequently utilized to set up
a standardized ELISA. To evaluate the novel assay, labo-
ratory A examined sera from North American patients with
clinically and pathologically diagnosed definite sIBM
(n = 17), suspected sIBM (n = 14), myositis controls
(n = 110), non-myositis autoimmune controls (n = 93)
and healthy subjects (n = 52). Laboratory B analyzed a
Dutch cohort of definite sIBM patients (n = 51) and
healthy controls (n = 202).
Results Anti-cN-1A reactivity was most frequent in defi-
nite sIBM (39.2–47.1%), but absent in biopsy-proven
classic polymyositis or dermatomyositis. Overall diagnos-
tic sensitivity and specificity amounted to 35.5 and 96.1%
(laboratory A) and 39.2 and 96.5% (laboratory B).
Conclusions Anti-cN-1A autoantibodies were detected by
ELISA with moderate sensitivity, but high specificity for
sIBM and may therefore help diagnose this infrequent and
difficult-to-diagnose myopathy. The novel anti-cN-1A IgG
ELISA can improve and accelerate the diagnosis of sIBM
using sera where muscle biopsy is delayed or unfeasible.
Keywords Anti-cN-1A  Anti-Mup44  Autoantibodies 
Autoimmunity  ELISA  Myopathy  Sporadic inclusion
body myositis
Abbreviations
cN-1A Cytosolic 50-nucleotidase 1A
ELISA Enzyme-linked immunosorbent assay
Ig Immunoglobulin
IIM Idiopathic inflammatory myopathy
sIBM Sporadic inclusion body myositis
Introduction
Sporadic inclusion body myositis (sIBM) is the most
common acquired myopathy in patients over 50 years old
[1, 2]. sIBM has a male predominance and a prevalence of
1–71 people per million individuals, rising up to
139 per million among people aged above 50 years and
varying between different populations [3–10]. Its primary
cause is still controversial, but autoimmune and
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degenerative processes are assumed to be pathogenically
relevant, involving a complex interaction between, for
example, environmental triggers, genetic susceptibility,
aging, oxidative and endoplasmic reticulum stress, mito-
chondrial abnormalities and aberrant myoproteostasis
[11–13].
sIBM is classified as an idiopathic inflammatory
myopathy (IIM), along with polymyositis, dermatomyositis
and immune-mediated necrotizing myopathies [14]. The
clinical manifestations of sIBM are typically related to
muscle weakness and atrophy, preferentially affecting the
quadriceps femoris, as well as the wrist and finger flexors.
Other muscle groups (e.g., finger extensors, upper arm
muscles, ankle dorsiflexors, paraspinal, facial and oropha-
ryngeal muscles) can also be affected to varying degrees.
Asymmetrical involvement is common, with the non-
dominant side showing more severe manifestations in most
cases. The presenting symptoms include, among others,
motor deficits (e.g., difficulties in standing up, climbing
stairs, walking, gripping), falls, foot drop, muscle wasting
and dysphagia. The disease course is chronic and slowly
progressive, leading to severe disability, often with
wheelchair dependency [15–17]. Muscle tissue in sIBM is
characterized by inflammatory and degenerative changes,
such as endomysial inflammatory infiltrates (macrophages,
CD8? T cells), myofiber MHC class I and II upregulation,
rimmed vacuoles, congophilic inclusions, sarcoplasmic
protein aggregates (e.g., amyloid-b, p62, TDP-43) and
mitochondrial abnormalities (e.g., cytochrome c oxidase
negative myofibers) [15, 18, 19]. However, due to their
patchy distribution and absence in early disease stages,
some of these histological markers are not detectable in up
to 30% of patients with clinically typical sIBM, thus
causing diagnostic difficulty and delay [2, 20–22].
The diagnosis of sIBM is suspected on clinical grounds
and confirmed by the above-mentioned key pathological
features on muscle biopsy [23–27]. In addition, magnetic
resonance imaging, electromyography and laboratory test-
ing (e.g., serum creatine kinase level, autoantibodies) can
aid the diagnosis [15, 28].
In 2013, the target of the sIBM-associated anti-Mup44
autoantibodies was identified as cytosolic 50-nucleotidase
1A (cN-1A, cN1A, NT5C1A, Mup44) [29–31], a 41 kDa
enzyme that is most abundant in the skeletal muscle, cat-
alyzing nucleotide hydrolysis and regulating nucleotide
metabolism [32, 33]. In patients with sIBM, the aberrant
accumulation of cN-1A in areas of myofiber degeneration
may contribute to its antigenicity, providing a plausible
link between myodegenerative and autoimmune features in
disease pathogenesis [30]. Anti-cN-1A autoantibodies are
currently the only known serum biomarker for sIBM [2]
and have the potential of early diagnosis and improving the
management of patients with suspected sIBM. This is
particularly important considering an initial misdiagnosis
rate of approximately 30–53%, a mean delay to diagnosis
of 4.9–8 years [7, 17, 34] and, in many cases, the need for
multiple muscle biopsies before it is possible to establish
the correct diagnosis [20, 21, 35]. In particular, the clinical
distinction between sIBM and polymyositis can be chal-
lenging, the latter being the most common initial misdi-
agnosis. Recent studies have reported anti-cN-1A reactivity
in the serum of 33–76% patients with sIBM, but in not
more than 5% of patients with polymyositis, with an
overall specificity varying between 87 and 100% depend-
ing on the methodology and cohorts studied
[29–31, 36–39]. Thus, the determination of anti-cN-1A
autoantibodies is useful for distinguishing sIBM from other
inflammatory myopathies. Such a distinction is crucial for
therapeutic decisions since sIBM, in contrast to
polymyositis, is poorly responsive to conventional
immunotherapies [40].
In this study, the diagnostic performance of a novel,
commercially available ELISA for the standardized
detection of anti-cN-1A autoantibodies was evaluated at
two reference laboratories using serum panels from clini-
cally and pathologically characterized sIBM patients and
various controls. Additionally, the assay was compared to
established in-house tests.
Methods
Patients and serum samples
Serum samples collected at the Rheumatology Diagnostics
Laboratory (RDL Inc., Los Angeles, CA, USA) were
obtained from North American patients with clinically and
pathologically diagnosed definite sIBM (n = 17), sus-
pected sIBM (n = 14) and other myopathies (n = 110)
[including polymyositis (n = 7), dermatomyositis (n = 4),
unspecified myositis without sIBM (n = 94), muscle
atrophy (n = 1) and myonecrosis (n = 4)]. The diagnosis
of sIBM was established according to the European Neu-
romuscular Centre (ENMC) criteria [26]. The Bohan and
Peter’s criteria were used for the classification of
polymyositis and dermatomyositis [41]. Sera from patients
clinically and serologically diagnosed with systemic lupus
erythematosus (n = 33), scleroderma (n = 20), Sjo¨gren’s
syndrome (n = 20) and rheumatoid arthritis (n = 20) as
well as healthy subjects (n = 52) were also collected at the
same center and included as controls.
Sera from two other cohorts were analyzed in parallel,
including samples from Dutch patients with clinically and
pathologically diagnosed definite sIBM (n = 51) obtained
from the Radboud University Medical Center (Nijmegen,
The Netherlands) and samples from healthy controls
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(n = 202) collected at the University Medical Center
Schleswig–Holstein, Campus Lu¨beck (Lu¨beck, Germany).
The Dutch sIBM patients fulfilled the ENMC criteria for
sIBM [27], while poly- and dermatomyositis were differ-
entiated based on the diagnostic criteria of Tanimoto et al.
[42].
Serum samples were tested anonymously to maintain
confidentiality. All study procedures were in accordance
with the ethical standards of the institutional research
committees and with the Helsinki Declaration.
Heterologous expression of recombinant human cN-
1A
cDNA encoding full-length human cN-1A according to
UniProt accession number Q9BXI3 was integrated in the
prokaryotic expression vector pET24d (Novagen, Darm-
stadt, Germany). The protein with a C-terminal hexa-His
tag was produced in Escherichia coli Roset-
taBlue(DE3)pLacI (Novagen) and purified using Ni-NTA
affinity chromatography (Qiagen, Hilden, Germany) as
described [43]. The purified antigen was analyzed by
denaturing electrophoresis using the NuPAGE Novex
4–12% Bis–Tris gradient gel system according to the
manufacturer’s instructions (Invitrogen, Karlsruhe, Ger-
many) and by MALDI-TOF mass spectrometry [44].
Anti-cN-1A IgG ELISA
Microtiter plates (Nunc, Roskilde, Denmark) were coated
with cN-1A (2.5 lg/ml in PBS, pH 7.5) overnight at 4 C,
washed with PBS containing 0.05% (v/v) Tween-20 and
blocked with 0.1% (w/v) casein in PBS for 2 h, followed
by another washing step. The determination of anti-cN-1A
autoantibodies was performed according to the manufac-
turer’s instructions (Euroimmun, Lu¨beck, Germany) using
the coated microtiter plates and standardized reagents
provided with the test kits. Briefly, sera diluted 1:101 in the
sample buffer were applied to the wells and incubated for
30 min. Bound antibodies were detected by adding rabbit
anti-human IgG peroxidase conjugate for 30 min, followed
by staining with tetramethylbenzidine for 15 min. The
enzymatic reaction was stopped with 0.5 mol/l sulfuric
acid. The optical density (OD) was measured photometri-
cally at 450 nm (reference 620 nm). A calibrator was
included in each run. As a result of receiver-operating
characteristic (ROC) analysis for the assessment of assay
accuracy, OD450 values of patient samples equal to or
greater than the OD450 value of the calibrator (cutoff)
were considered positive [ratio (OD450 sample/OD450
calibrator) C1.0]. At RDL, an in-house calibrator was
utilized for the ratio calculation (OD450 sample/OD450
calibrator). Then a unit multiplier was used to determine
the arbitrary units. The unit cutoff was based on the mean
of 52 healthy individuals plus three standard deviations
(mean ? 3 SD). The results of less than 25 units were
considered negative.
Peptide ELISA
ELISAs based on three synthetic 23-mer peptides corre-
sponding to the major epitope regions of cN-1A were
performed as described previously [38]. Sera were assessed
as reactive if their OD450 value was above the established
cutoff value for at least one of the peptide antigens (peptide
1, OD450 C 0.384; peptide 2, OD450 C 0.270; peptide 3,
OD450 C 0.280). For each serum sample, only the maxi-
mum OD450 value of the three peptide ELISAs (maximum
peptide reactivity) was used for correlation analysis.
Immunoprecipitation assay
Immunoprecipitation was performed with radiolabeled
in vitro translated full-length cN-1A, followed by SDS-
PAGE and quantification by phosphorimaging, as descri-
bed previously [31]. To differentiate between high and low
cN-1A immunoprecipitation efficiencies, cutoff levels of 5
and 1% (fraction of input cN-1A precipitated) were arbi-
trarily chosen.
Determination of other autoantibodies
Autoantibodies against myositis-related autoantibodies
were determined using the Euroline Autoimmune Inflam-
matory Myopathies 16 Ag (IgG) immunoblot according to
the instructions of the manufacturer (Euroimmun, Lu¨beck,
Germany), allowing monospecific detection of Ro-52,
isoleucyl-tRNA synthetase (OJ), glycyl-tRNA synthetase
(EJ), alanyl-tRNA synthetase (PL-12), threonyl-tRNA
synthetase (PL-7), 54 kDa recombinant signal recognition
particle (SRP), histidyl-tRNA synthetase (Jo-1), PM-Scl75,
PM-Scl100, Ku, SUMO activating enzyme subunits 1
(SAE1), MJ-p140-MU 140 kD protein/MORC3 (NXP2),
melanoma differentiation-associated gene 5 (MDA5),
transcriptional intermediary factor 1-gamma (TIF1c),
chromodomain-helicase-DNA-binding protein 4 (Mi-2b)
and chromodomain-helicase-DNA-binding protein 3 (Mi-
2a).
Statistical analysis
Statistical analyses were performed using GraphPad Prism
6 (GraphPad Software Inc., La Jolla, CA, USA) and Sig-
maPlot 13.0 analysis software (SSI, San Jose, CA, USA).
Confidence intervals (CI 95%) were calculated according
to the modified Wald method. The degree of correlation
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was evaluated by calculating the Pearson’s or the Spear-
man’s rank order correlation coefficient (r). P values\0.05
were considered to be significant.
Results
Recombinant full-length human cN-1A was expressed in
E. coli as His-tagged protein and purified by immobilized
metal chelate affinity chromatography. When separated by
SDS-PAGE, the protein migrated consistent with its cal-
culated molecular mass of 41 kDa (taking into account the
additional mass resulting from fused amino acids encoded
by the expression vector, such as the His tag) and showed a
high degree of purity (Fig. 1). MALDI-TOF mass spec-
trometry confirmed protein identity. A semi-quantitative
ELISA based on the purified antigen was developed for the
standardized detection of serum anti-cN-1A IgG autoanti-
bodies. The diagnostic performance of this assay was
studied at two independent reference laboratories.
At the RDL Reference Laboratory (Los Angeles, CA,
USA), reactivity against cN-1A was detected in 8 (47.1%)
of 17 North American patients with definite sIBM and in 3
(21.4%) of 14 patients with suspected sIBM. Among 110
patients with non-sIBM myopathies (myositis controls),
positive reactivity was found in 4 (3.6%) cases, all of
which had been classified as having unspecified myositis
without sIBM. In contrast, all patients with biopsy-proven
classical polymyositis, dermatomyositis, muscle atrophy or
myonecrosis were found to be anti-cN-1A negative. Out of
93 sera from other autoimmune disease controls, 5 (5.4%)
showed positive reactivity, of which 2 were from patients
with systemic lupus erythematosus, 2 with scleroderma and
1 with rheumatoid arthritis. None of the patients with
Sjo¨gren’s syndrome and only 1 (1.9%) of 52 healthy con-
trols were found to be positive. Referring to the total of 31
patients with definite or suspected sIBM and 255 controls,
the diagnostic sensitivity and specificity of this novel
ELISA amounted to 35.5 and 96.1%, respectively
(Table 1).
In parallel, two further cohorts were analyzed by means
of the anti-cN-1A IgG ELISA at the Institute for Experi-
mental Immunology (Lu¨beck, Germany). Here, reactivity
against cN-1A was present in 20 (39.2%) of 51 Dutch
patients with definite sIBM and in 7 (3.5%) of 202 healthy
subjects, resulting in a sensitivity of 39.2% and specificity
of 96.5% (Table 2).
The Dutch patients’ sera were also examined for anti-
cN-1A reactivity using previously published ELISAs based
on three synthetic peptides representing immunodominant
cN-1A epitopes, and for their efficiency to immunopre-
cipitate recombinant in vitro translated full-length cN-1A.
As depicted in the scatter plots in Fig. 2, there was a sig-
nificant correlation of the novel anti-cN-1A IgG ELISA
with reactivity measured by the peptide ELISA
(r = 0.7884, P\ 0.0001) and the immunoprecipitation
assay (r = 0.8320, P\ 0.0001).
Testing for myositis-related autoantibodies in a subset of
75 sIBM sera revealed reactivity against Ro-52 in 14.7%,
against PL-7, PL-12, SRP and Ku in 4% each, against
TIF1c in 2.7%, and against OJ, EJ, Jo-1, PM-Scl75, PM-
Scl100, and Mi-2b in 1.3% each (Table 3).
Spearman’s rank order correlation revealed a moderate
relationship between anti-cN-1A reactivity and the pres-
ence of Ro-52 (r = 0.381, P\ 0.01) and SRP (r = 0.315,
P\ 0.001) autoantibodies in sIBM, whereas Pearson’s
correlation revealed a moderate relationship between anti-
cN-1A and OJ autoantibodies (r = 0.312, P\ 0.01). No
correlation was detected between anti-cN-1A and any other
analyzed autoantibodies.
Discussion
In 2013, cN-1A was identified as a major immune target in
sIBM [30, 31]. Circulating autoantibodies against this
muscle antigen represent a new serologic marker for
diagnosing sIBM, which is at times clinically indistin-
guishable from other forms of IIM, such as polymyositis
[2]. In the present study, anti-cN-1A IgG autoantibodies
were detected by a newly developed commercial ELISA
with a diagnostic sensitivity of 35.5–39.2%, reaching the
Fig. 1 Analysis of purified
recombinant cN-1A. Molecular
weight markers (lane 1) and
1 lg of purified cN-1A (lane 2)
were separated by sodium
dodecyl sulfate–polyacrylamide
gel electrophoresis followed by
Coomassie staining. The
molecular masses (kDa) of the
size markers are indicated on
the left
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highest levels (47.1%) in a subgroup of patients with def-
inite sIBM and a specificity of more than 96%. Impor-
tantly, sensitivity and specificity measured at two different
laboratories using different serum panels were highly
similar. Our data compare well with previous reports
where, depending on the methods and cohorts studied, anti-
cN-1A reactivity had been detected in the serum of
33–76% of sIBM patients, with an overall specificity of
87–100% [29–31, 36–39] (Table 4). Noteworthy, assays
with a high sensitivity ([50%) were either based on
immunoblot analysis or on ELISA for combined Ig isotype
detection (IgM, IgA and IgG) and, in most cases, were
associated with lower levels of specificity (\95%) [36, 39].
The newly developed ELISA is based on full-length cN-
1A antigen and represents the first fully standardized
commercial assay for routine anti-cN-1A testing. Consid-
ering that the complete spectrum of linear and/or confor-
mational immunodominant epitopes is yet to be identified,
the use of the full-length antigen may be diagnostically
advantageous compared to assays based on peptides. When
the reactivity of the same patient samples in the novel
ELISA was compared with that in previously published
synthetic cN-1A peptide ELISAs and with their efficiency
in immunoprecipitation of recombinant in vitro translated
full-length cN-1A [31, 38], good correlations were
observed. Besides its commercial availability, the advan-
tages of the new assay are that, one, the full-length antigen
is used, allowing the detection of autoantibodies to most, if
not all, epitopes; two, only a single assay has to be per-
formed to detect the antibodies, whereas the reactivity with
Table 1 Anti-cN-1A reactivity in sera from patients with sporadic inclusion body myositis, disease controls and healthy controls as determined
by anti-cN-1A IgG ELISA at the RDL Reference Laboratory (Los Angeles, CA, USA)
Cohorts Subgroups n Anti-cN-1A ELISA (IgG)
Positive Negative Sensitivity (CI 95%) Specificity (CI 95%)
sIBM Definite sIBM 17 8 9 47.1% (26.2–69.0%)
Suspected sIBMa 14 3 11 21.4% (6.8–48.3%)
Total sIBM 31 11 20 35.5% (21.1–53.1%)
Myositis controls Polymyositis 7 0 7 100.0% (59.6–100.0%)
Dermatomyositis 4 0 4 100.0% (45.4–100.0%)
Unspecified myositis
without sIBMb
94 4 90 95.7% (89.2–98.7%)
Muscle atrophy 1 0 1 100.0% (16.8–100.0%)
Myonecrosis 4 0 4 100.0% (45.4–100.0%)
Other autoimmune
disease controls
Systemic lupus
erythematosus
33 2 31 93.9% (79.4–99.3%)
Scleroderma 20 2 18 90.0% (68.7–98.4%)
Sjo¨gren’s syndrome 20 0 20 100.0% (81.0–100.0%)
Rheumatoid arthritis 20 1 19 95.0% (74.6–100.0%)
Healthy controls 52 1 51 98.1% (88.9–100.0%)
Total controls 255 10 245 96.1% (92.8–98.0%)
CI confidence interval, cN-1A cytosolic 50-nucleotidase 1A, sIBM sporadic inclusion body myositis
a Suspected sIBM include biopsy readings of possible, probable and doubtful sIBM patients
b Unspecified myositis without sIBM include idiopathic inflammatory myopathy (polymyositis, dermatomyositis and uncharacterized myositis)
with no available biopsy data for this study
Table 2 Anti-cN-1A reactivity in sera from patients with sporadic inclusion body myositis (sIBM) and in healthy controls as determined by anti-
cN-1A IgG ELISA at the Institute for Experimental Immunology (Lu¨beck, Germany)
Cohorts n Anti-cN-1A ELISA (IgG)
Positive Negative Sensitivity (CI 95%) Specificity (CI 95%)
sIBM 51 20 31 39.2% (27.0–52.9%)
Healthy controls 202 7 195 96.5% (92.9–98.5%)
CI confidence interval, cN-1A cytosolic 50-nucleotidase 1A, sIBM sporadic inclusion body myositis
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three distinct antigenic peptides has to be determined in
three separate ELISAs; three, no laborious and special
infrastructure requiring procedures, such as those for
immunoprecipitation, are required; and four, a standardized
assay can be applied in different laboratories.
The moderate prevalence of anti-cN-1A autoantibodies
in sIBM does not reduce their significance as a serologic
marker. Similar or lower prevalence levels are also char-
acteristic for other serologic parameters. For example, the
prevalence of myositis-specific autoantibodies (MSA: anti-
Jo-1, anti-Mi-2, anti-SRP, anti-PL-7, anti-PL-12, anti-EJ,
anti-OJ) and myositis-associated autoantibodies (MAA:
anti-SSA/Ro-52, anti-Ku, anti-PM/Scl75, anti-PM/Scl100)
in polymyositis/dermatomyositis does not exceed a total of
34.4% (MSA) and 41.4% (MAA), respectively [45].
Reactivity to individual MSA and MAA with low fre-
quencies in sIBM patients is in accordance with previous
publications [46]. Detected correlations between reactivity
to anti-cN-1A and other autoantibodies have to be con-
sidered with caution due to the small sample numbers,
whereby the correlation between anti-cN-1A and anti-Ro-
52 seems to be likely. Interestingly, a concurrence of anti-
Ro-52 with anti-Jo-1 in idiopathic inflammatory myopathy
was reported earlier, and anti-Ro-52 and anti-cN-1A might
be coupled in a similar way [47].
There is not yet clear evidence regarding clinical or
pathophysiological differences between anti-cN-1A-posi-
tive and -negative sIBM patients. So far, only one study has
provided data indicating that anti-cN-1A seropositivity
may be associated with a more aggressive form of IBM,
including more prominent motor, bulbar and respiratory
involvement [37].
In patients with biopsy-proven classic polymyositis or
dermatomyositis, we observed a specificity of 100%, con-
firming the utility of anti-cN-1A autoantibodies in distin-
guishing sIBM from polymyositis (but given the small
number of patients, these results have to be interpreted with
caution). In a control group of 94 patients classified as
having unspecified myositis without sIBM (no biopsy data
available), anti-cN-1A reactivity was positive in 4 (4.3%)
cases that were polymyositis or dermatomyositis. However,
this is far below the prevalence observed in sIBM and
consistent with recent studies where anti-cN-1A positivity
was observed in not more than 5% of patients with
polymyositis [30, 31, 38, 39].
Interestingly, in previous studies, anti-cN-1A autoanti-
bodies were also found at a moderate prevalence in patients
with Sjo¨gren’s syndrome (23–36%) and systemic lupus
erythematosus (14–20%) [38, 39]. This finding was not
confirmed by the present study where anti-cN-1A reactivity
was detectable in none of the patients with Sjo¨gren’s
syndrome and in not more than 6.1% of patients with
systemic lupus erythematosus, although the relatively small
patient numbers allow only limited conclusions. In addi-
tion, 5.0% of patients with rheumatoid arthritis and 10.0%
of patients with scleroderma were found to be anti-cN-1A
positive. This is, however, of minor relevance for clinical
practice because differentiating patients with sIBM from
those with Sjo¨gren’s syndrome, systemic lupus erythe-
matosus or other non-myositis autoimmune conditions is
a
b
Fig. 2 Correlation analysis. Reactivity of serum samples from Dutch
patients with sporadic inclusion body myositis was measured by anti-
cN-1A IgG ELISA (Euroimmun) based on recombinant full-length
cN-1A, by ELISAs based on three synthetic peptides representing
major cN-1A epitopes (n = 51), and by immunoprecipitation (IP) of
in vitro translated full-length cN-1A (n = 30). Results by anti-cN-1A
IgG ELISA were plotted against a the maximum OD450 values
measured by either of the three peptide ELISAs and b against the
efficiency of immunoprecipitation. Dotted lines represent cutoff
values (anti-cN-1A IgG ELISA, ratio C1.0; IP high efficiency,[5%
of input; IP low efficiency,[1% of input). In panel a, triangles/
circles depict serum specimens with a maximum OD450 value below/
above the cutoff value of the respective peptide ELISA (peptide 1,
OD450 C 0.384; peptide 2, OD450 C 0.270; peptide 3,
OD450 C 0.280). Correlation was evaluated by Pearson’s correlation
coefficients (r) as indicated. P values \0.05 were considered
significant
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Table 3 Reactivity of myositis-
related autoantibodies in sera
from patients with sporadic
inclusion body myositis (sIBM)
as determined by Euroline
Autoimmune Inflammatory
Myopathies 16 Ag (IgG)
immunoblot (Euroimmun)
Myositis-related autoantibodies sIBM patients
All
(n = 75)
Anti-cN-1A-positive
(n = 28)
Correlation
to anti-cN-1A
Positive Positive
n Frequency n Frequency r
Anti-Ro-52 11 14.7% 9 32.1% 0.381a
Anti-OJ 1 1.3% 1 3.6% 0.312c
Anti-EJ 1 1.3% 0 0.0%
Anti-PL-12 3 4.0% 2 7.1%
Anti-PL-7 3 4.0% 1 3.6%
Anti-SRP 3 4.0% 3 10.7% 0.315b
Anti-Jo-1 1 1.3% 0 0.0%
Anti-PM-Scl75 1 1.3% 0 0.0%
Anti-PM-Scl100 1 1.3% 1 3.6%
Anti-Ku 3 4.0% 2 7.1%
Anti-SAE1 0 0.0% 0 0.0%
Anti-NXP2 0 0.0% 0 0.0%
Anti-MDA5 0 0.0% 0 0.0%
Anti-TIF1c 2 2.7% 1 3.6%
Anti-Mi-2b 1 1.3% 0 0.0%
Anti-Mi-2a 0 0.0% 0 0.0%
cN-1A cytosolic 50-nucleotidase 1A, sIBM sporadic inclusion body myositis
a P\ 0.001, Spearman’s rank order correlation
b P\ 0.01, Spearman’s rank order correlation
c P\ 0.01, Pearson’s correlation
Table 4 Diagnostic performance of anti-cN-1A assays for the diagnosis of sporadic inclusion body myositis
References Method Number of
sIBM
patients
Number of
controls
Sensitivity Specificity
(non-sIBM
muscle
diseases)
Specificity
(total
controls)
Salajegheh
et al. [29]
Western blot against human skeletal muscle extract 25 40 52% 100% 100%
Larman et al.
[30]
Dot blot against a synthetic 36-amino acid cN-1A peptide
(high cutoff)
47 153 34%a
(70%)b
98%a
(92%)b
99%a
Pluk et al. [31] Immunoprecipitation with in vitro translated recombinant
cN-1A (high cutoff)
94 172 33%a 96%a 97%a
Greenberg
et al. [36]
ELISA (IgG) using recombinant cN-1A 50 155 51%b ND 94%b
ELISA (combined IgG/IgA/IgM) using recombinant cN-
1A
50 155 76%b ND 91%b
Goyal et al.
[37]
Western blot against recombinant cN-1A expressed in
HEK293 cells, ELISA using recombinant cN-1A
25 ND 72% ND ND
Herbert et al.
[38]
ELISA using three synthetic cN-1A peptides (a` 23 amino
acids) covering the major immunodominant epitopes
238 524 37% 96% 94%
Lloyd et al.
[39]
Western blot against recombinant cN-1A expressed in
HEK293 cells
117 383 61% 87% 87%
Kramp et al.
(this study)
ELISA (Euroimmun, IgG) using recombinant full-length
cN-1A; Laboratory A
31 255 36% 96% 95%
ELISA (Euroimmun, IgG) using recombinant full-length
cN-1A; Laboratory B
51 202 39% ND 97%
cN-1A cytosolic 50-nucleotidase 1A, HEK293 human embryonic kidney 293 cell line, ND not determined, sIBM sporadic inclusion body myositis
a Data based on a high cutoff point
b Data obtained by receiver-operating characteristics (ROC) curve analysis using a cutoff for optimal assay accuracy
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usually clinically and immunologically straightforward
[38, 39].
Currently, the diagnosis of sIBM is mainly based on
clinical features and histopathological analyses of muscle
biopsy specimens [26]. Misdiagnosis and delayed diagnosis
occur frequently [7, 17, 34]. The detection of anti-cN-1A
autoantibodies may facilitate the early diagnosis of sIBM,
especially when the clinical presentation is not distinctive
and/or when typical pathological features are not yet
detectable. Therefore, and considering that treatment
options and responses differ between the different forms of
myositis, serologic testing is highly beneficial to improve
the care and management of patients with suspected sIBM.
In conclusion, a sensitive and highly specific ELISA for
the standardized detection of anti-cN-1A autoantibodies in
sIBM has been developed. This assay can support the
differential diagnosis of sIBM, particularly the distinction
from other inflammatory myopathies, using sera where
muscle biopsy is delayed or unfeasible, thus improving
patient care. Further studies are in progress to compare
larger cohorts by standardized testing to fully investigate
the prevalence of anti-cN-1A autoantibodies in myositis
and other autoimmune diseases. In addition, studies
addressing the association of anti-cN-1A autoantibodies
with clinical features in large patient groups are currently
being performed and will provide more insight into the
clinical meaningfulness of anti-cN-1A testing.
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